Alpha-interferon for intractable pruritus in polycythaemia vera

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial.

Leukemia·2024

Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia.

Journal of internal medicine·2017

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.

Leukemia·2017

Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy.

Leukemia·2017

Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.

Leukemia·2016

6-Mercaptopurine, Still Valuable for the Palliative Treatment of Acute Myeloid Leukaemia.

Hematology (Amsterdam, Netherlands)·2016

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Lancet (London, England)·2026

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Lancet (London, England)·2026

Advancing the relevance of clinical trials for older patients.

Lancet (London, England)·2026

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Lancet (London, England)·2026

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Lancet (London, England)·2026

Postpartum-onset anti-PM/Scl-positive dermatomyositis-systemic sclerosis overlap syndrome with reversible interstitial lung disease: a case report.

Frontiers in medicine·2026

Severe recurrent anaphylaxis: investigating underlying mechanisms beyond IgE-mediated allergy - a case report.

Frontiers in allergy·2026

Upadacitinib for refractory generalized lichen sclerosus: a case report and brief literature review.

Frontiers in immunology·2026

Case Report: A case report of bullous pemphigoid triggered by sintilimab (PD-1 inhibitor).

Frontiers in immunology·2026

Efficacy and safety of dupilumab following discontinuation of JAK inhibitors in patients with moderate-to-severe atopic dermatitis: a single-center retrospective study.

Frontiers in immunology·2026

Successful management of pembrolizumab-associated Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient with uterine serous carcinoma: a case report.

Frontiers in immunology·2026

Related Experiment Videos

Alpha-interferon for intractable pruritus in polycythaemia vera

Related Concept Videos

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial.

Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia.

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.

Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy.

Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.

6-Mercaptopurine, Still Valuable for the Palliative Treatment of Acute Myeloid Leukaemia.

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Advancing the relevance of clinical trials for older patients.

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Postpartum-onset anti-PM/Scl-positive dermatomyositis-systemic sclerosis overlap syndrome with reversible interstitial lung disease: a case report.

Severe recurrent anaphylaxis: investigating underlying mechanisms beyond IgE-mediated allergy - a case report.

Upadacitinib for refractory generalized lichen sclerosus: a case report and brief literature review.

Case Report: A case report of bullous pemphigoid triggered by sintilimab (PD-1 inhibitor).

Efficacy and safety of dupilumab following discontinuation of JAK inhibitors in patients with moderate-to-severe atopic dermatitis: a single-center retrospective study.

Successful management of pembrolizumab-associated Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient with uterine serous carcinoma: a case report.

Related Experiment Videos

Alpha-interferon for intractable pruritus in polycythaemia vera

Related Concept Videos

Related Articles